| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IMRX | Stock Option | Disposed to Issuer | $0 | -101K | -100% | $0.00* | 0 | May 21, 2024 | Class A Common Stock | 101K | $15.00 | Direct | F1, F2 |
| transaction | IMRX | Stock Option | Award | $0 | +101K | $0.00 | 101K | May 21, 2024 | Class A Common Stock | 101K | $3.01 | Direct | F1, F2 | |
| transaction | IMRX | Stock Option | Disposed to Issuer | $0 | -47.3K | -100% | $0.00* | 0 | May 21, 2024 | Class A Common Stock | 47.3K | $9.66 | Direct | F1, F3 |
| transaction | IMRX | Stock Option | Award | $0 | +47.3K | $0.00 | 47.3K | May 21, 2024 | Class A Common Stock | 47.3K | $3.01 | Direct | F1, F3 | |
| transaction | IMRX | Stock Option | Disposed to Issuer | $0 | -143K | -100% | $0.00* | 0 | May 21, 2024 | Class A Common Stock | 143K | $4.25 | Direct | F1, F4 |
| transaction | IMRX | Stock Option | Award | $0 | +143K | $0.00 | 143K | May 21, 2024 | Class A Common Stock | 143K | $3.01 | Direct | F1, F4 | |
| transaction | IMRX | Stock Option | Disposed to Issuer | $0 | -93K | -100% | $0.00* | 0 | May 21, 2024 | Class A Common Stock | 93K | $6.09 | Direct | F1, F5 |
| transaction | IMRX | Stock Option | Award | $0 | +93K | $0.00 | 93K | May 21, 2024 | Class A Common Stock | 93K | $3.01 | Direct | F1, F5 |
| Id | Content |
|---|---|
| F1 | On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. |
| F2 | The option vests and becomes exercisable as to 25% of the underlying shares on July 15, 2022 and then in equal monthly installments over the subsequent three years, subject to Mr. Bookman's continued employment through each applicable vesting date. |
| F3 | The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. |
| F4 | The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. |
| F5 | The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. |